LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
== Biological function == Lipoic acid is a cofactor for five enzymes or classes of enzymes: pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, the glycine cleavage system, branched-chain alpha-keto acid dehydrogenase, and the α-oxo(keto)adipate dehydrogenase. The first two are critical to the citric acid cycle. The GCS regulates glycine concentrations. HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, and HDAC10 are targets of the reduced form (open dithiol) of (R)-lipoic acid.
Coller (1966), father of Abciximab, vice president and physician-in-chief at Rockefeller University Peter Gray (1966), psychologist; professor at Boston College Brian Weiss (1966), psychiatrist noted for his research on reincarnation and past life regression Richard Axel (1967), winner of the Nobel Prize in Physiology or Medicine for studying the operations of the olfactory system Nai Phuan Ong (1967), professor of Physics at Princeton University Nick Scoville (1967), professor of astronomy at California Institute of Technology Robert Wald (1968), theoretical physicist at the University of Chicago Sidney R. Nagel (1969), University of Chicago physicist specializing in the complex physics of everyday materials Thomas B. Kornberg (1970), biochemist who was the first to purify and characterize DNA polymerase II and DNA polymerase III Harold J. Vinegar (1970), former chief scientist for physics of Shell plc, professor at Ben-Gurion University of the Negev Franklin G. Miller (1971), bioethicist at the National Institutes of Health Eric Rose (1971), cardiothoracic surgeon known for performing the first successful paediatric heart transplant; former president of the International Society for Heart and Lung Transplantation Paul S. Appelbaum (1972), psychiatrist credited with conceptualizing the idea of therapeutic misconception Steven M. Bellovin (1972), professor of computer science at Columbia University and chief technologist of Federal Trade Commission Rick L.
Many biologics, skin substitutes, biomembranes and scaffolds have been developed to facilitate wound healing through various mechanisms. Other recent developments has been the renewed focus on the prominent patient concern of pain. Burn patients and others affected by severe wounds often report pain as the dominant negative impact of the wounds on their lives. Clinical management of the pain associated with chronic wounds has been an emergency wound treatment priority and is now viewed as an integral part of treatment.
Sources: en.wikipedia.org
For several years after World War II, the United States developed and maintained a strategic force based on the Convair B-36 bomber that would be able to attack any potential enemy from bomber bases in the United States. It deployed atomic bombs around the world for potential use in conflicts. Over a period of a few years, many in the American defense community became increasingly convinced of the invincibility of the United States to a nuclear attack. Indeed, it became generally believed that the threat of nuclear war would deter any strike against the United States. Many proposals were suggested to put all American nuclear weapons under international control (by the newly formed United Nations, for example) as an effort to deter both their usage and a nuclear arms race. However, no terms could be arrived at that would be agreed upon by both the United States and the Soviet Union.
Towards the south and southwest lie the northern parts of the Central Uplands: the Weser Uplands and the Harz Mountains. Between these two lie the Lower Saxon Hills, a range of low ridges. The region in the northeast, the Lüneburg Heath (Lüneburger Heide), is the largest heathland area of Germany. In the Middle Ages, the town of Lüneburg was wealthy due to salt-mining and the salt trade. To the north the Elbe valley separates Lower Saxony from Hamburg, Schleswig-Holstein, Mecklenburg-Vorpommern, and Brandenburg. The left banks of the Elbe downstream Hamburg are known as the Altes Land (Old Country). Due to its gentle local climate and fertile soil, it is the state's largest area of fruit farming, its chief produce being apples. The modern state of Lower Saxony was created from parts of the British occupation zone after World War II by the merger of the State of Hanover with the three smaller free states of Braunschweig, Oldenburg and Schaumburg-Lippe on 1 November 1946. As most of the new state's territory consisted of the historic Kingdom of Hanover, Lower Saxony adopted its coat of arms and other symbols.
Ellen McLain (born 1952 or 1953) is an American voice actress. She is best known for providing the voice of GLaDOS, the primary antagonist of the Portal video game series, the Combine Overwatch AI in Half-Life 2, and the Administrator, the announcer in Team Fortress 2. Her voice roles also include the Jaeger A.I. in Pacific Rim and The Witch in Left 4 Dead 2.
Sources: en.wikipedia.org
== Method == The RAST is a radioimmunoassay test to detect specific IgE antibodies to suspected or known allergens for the purpose of guiding a diagnosis about allergy. IgE is the antibody associated with Type I allergic response: for example, if a person exhibits a high level of IgE directed against pollen, the test may indicate the person is allergic to pollen (or pollen-like) proteins. A person who has outgrown an allergy may still have a positive IgE years after exposure. The suspected allergen is bound to an insoluble material and the patient's serum is added. If the serum contains antibodies to the allergen, those antibodies will bind to the allergen. Radiolabeled anti-human IgE antibody is added where it binds to those IgE antibodies already bound to the insoluble material. The unbound anti-human IgE antibodies are washed away. The amount of radioactivity is proportional to the serum IgE for the allergen. RASTs are often used to test for allergies when:
A variety of geologic and environmental settings have been proposed for an origin of life. These theories are often in competition with one another as there are many views of prebiotic compound availability, geophysical setting, and early life characteristics. The first organism on Earth likely differed from LUCA. Between the first appearance of life and where all modern phylogenies began branching, an unknown amount of time passed, with unknown gene transfers, extinctions, and adaptation to environmental niches. Modern phylogenies provide more genetic evidence about LUCA than about its precursors.
== Interactions == Mianserin may enhance the sedative effects of drugs such as alcohol, anxiolytics, hypnotics, or antipsychotics when co-administered. It may decrease the efficacy of antiepileptic medications. Carbamazepine and phenobarbital will cause the body to metabolize mianserin faster and may reduce its effects. There is a risk of dangerously low blood pressure if people take mianserin along with diazoxide, hydralazine, or nitroprusside. Mianserin can make antihistamines and antimuscarinics have stronger effects. Mianserin should not be taken with apraclonidine, brimonidine, sibutramine, or the combination drug of artemether with lumefantrine.
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.